Q2's Missing Datasets: Why Latin America Just Lost a Fast-Track FIH to Australia

first-in-human · FIH · clinical trial · clinical research · regulatory · ANVISA

This week the gap between Latin America’s regulatory promise and the data needed to prove it grew harder to ignore. Argentina’s first empirical readout on its 62-day approval cap is overdue, Brazil’s reliance-queue checkpoint passed without published metrics, and another minimally invasive neural-interface program chose Melbourne over LATAM for first-in-human work.- A neural-interface sponsor picks Australia, citing speed

Argentina’s 62-day FIH cap awaits its first empirical test

Brazil’s reliance queue passes a checkpoint with no public metrics

The UK’s new clinical trial framework enters into force April 28

Bolivia emerges as the next LATAM FIH option

A new FIFARMA report reframes LATAM’s research capacity storyTake a closer look at where first-in-human work is actually moving.Australia Wins Another FIH Program -- and the LATAM Frame TightensPhantom Neuro received approval on April 15 for the CYBORG Early Feasibility Study of its Phantom X minimally invasive muscle-machine interface, with up to 10 upper-limb amputees enrolled at Cabrini Health and ProMotion Prosthetics in Melbourne. The company’s CEO publicly cited “Australia’s efficient early-stage clinical trial pathways” as the reason for the site selection -- a framing now familiar to any LATAM-focused operator. The program’s eventual U.S. pivotal phase remains an open question.Why It Matters: Every neurotechnology FIH that lands in Australia rather than Latin America is a data point against the region’s competitive case. Closing the gap requires not only fast statutory caps but published evidence that those caps hold in practice.Argentina’s 62-Day Cap Awaits Its First Real NumberArgentina’s Disposicion 7516/2025 -- the rule that capped ANMAT clinical trial reviews at 62 calendar days -- has been operative since December 1, 2025. Trials submitted in the first weeks after the rule took effect should now have completed the cycle, which means Q2 2026 ought to deliver the first meaningful comparison between the statutory clock and the operational one. As of April 27, ANMAT had not yet published that data.- Statutory cap: 62 calendar days

First eligible cohort of trials: submitted Dec 2025 - Jan 2026

Q2 2026 publication of empirical timing: still pendingBottom Line: This is the single most consequential data point of the quarter. If the cap holds in practice, Argentina becomes the fastest FIH jurisdiction in Latin America. If it slips, the region’s headline regulatory reform will have to be argued on aspiration rather than evidence.ANVISA’s Reliance Queue: Checkpoint Reached, Metrics WithheldApril 14 was the first scheduled processing checkpoint for ANVISA’s dedicated reliance queue under RDC 997/2025. Two weeks later, the agency has released no queue statistics, no average processing times, and no public assessment of how the new Plano de Gestao da Avaliacao roadmaps are performing. The mechanisms -- dedicated CT submission queues, optimized technical assessment leveraging FDA and EMA decisions, queue substitution on sponsor withdrawal -- are confirmed in the latest Chambers Life Sciences guide. The numbers behind them are not.What to Focus On: Sponsors with prior FDA or EMA approval are watching for a reliance pathway that finishes inside 90 business days. Until ANVISA publishes the queue data, that promise remains an internal one.The UK’s New Clinical Trial Framework Lands April 28The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 take effect on April 28, 2026. The new framework combines ethics and MHRA review into a single decision, introduces risk-proportionate notifications for lower-risk studies, mandates public registration, and requires patient-centric communication. The result is a UK regime explicitly designed to compete with the EU’s Clinical Trials Regulation and with the faster jurisdictions in the Asia-Pacific.Why It Matters: Sponsors using Latin America as the speed leg of a UK-anchored multi-country program should map their LPLV dates against the April 28 cutover. The framework’s combined-review timetable will reset what counts as competitive turnaround in the rest of the trial network.Advance Your First-in-Human Trials with Confidencebioaccess® is the world’s only CRO dedicated exclusively to first-in-human clinical trials in Latin America, helping MedTech, biopharma, and radiopharma sponsors compress timelines and reduce cost without compromising regulatory rigor.- Country-aware pathway design across Argentina, Brazil, Colombia, Mexico, Panama, Bolivia, and other LATAM jurisdictions

End-to-end execution from regulatory submission through site activation, EDC, and monitoring

Direct, founder-led engagement built around the timelines startups actually faceSchedule your first-in-human trial consultation at bioaccessla.com.Bolivia Joins the LATAM FIH MapIn the past week, bioaccess® published four Bolivia-focused guides in four days -- covering investigational device exemption submission, clinical trial outsourcing, and the AGEMED regulatory pathway. The cadence signals an operational position bioaccess® has been building quietly: Bolivia as a fifth LATAM FIH option alongside Argentina, Brazil, Colombia, and the Panama-Mexico corridor. AGEMED’s published timing benchmarks are still being mapped against the more established agencies, but the entry point is now documented.Bottom Line: A wider LATAM map gives sponsors more leverage on cost, recruitment, and competitive site density -- provided the regulatory clock can be characterized accurately. Bolivia is now part of that conversation.FIFARMA Reframes LATAM’s Innovation StoryOn April 26, the Latin American Federation of the Pharmaceutical Industry published a new study on the region’s health innovation environment, covering scientific capacity, clinical research capacity, and regulatory readiness. The federation’s Latam Health Champions program drew 234 applications from 11 countries this cycle, with eight winners scheduled to present in Boston later this year. The data set offers the kind of cross-country baseline that has been missing from LATAM’s clinical research pitch.What to Focus On: Sponsors evaluating LATAM feasibility now have an institutional data point to triangulate against agency timelines, site networks, and patient access -- not a substitute for due diligence, but a useful reference layer.Key Takeaways- Phantom Neuro’s CYBORG EFS approval in Melbourne shows Australia continues to win minimally invasive neural-interface FIH programs.

Argentina’s 62-day FIH cap remains the most important LATAM regulatory variable of the quarter; the first empirical data is overdue.

ANVISA’s RDC 997/2025 reliance queue passed its April 14 checkpoint without publishing metrics, leaving sponsors without the evidence they need.

The UK’s new clinical trial regulations enter into force April 28 and will reshape multi-country timing for any LATAM-UK program.

Bolivia is now mapped as a fifth LATAM FIH option; AGEMED timing benchmarks are still being characterized.

FIFARMA’s April 26 innovation environment study gives sponsors a new institutional baseline for LATAM clinical research capacity.bioaccess® | Fast-Tracking First-in-Human Trials, Anywhere.: https://www.linkedin.com/company/bioaccessla

← All Global Trial Accelerators editions · Contact bioaccess®